Sitagliptin

Intervention Approved 2006

3 papers

PubChem 4369359 ChEBI 40237 MeSH D000068900

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

247 trials, 84 with no results posted

103 of 247 trials sponsored by its developers

Humans3

Trials

247

Approved

FDA Januvia
16 Oct 2006Diabetes Mellitus, Type 2
EMA Januvia
20 Mar 2007Diabetes Mellitus, Type 2, Diabetes Mellitus
EMA Xelevia
21 Mar 2007Diabetes Mellitus, Type 2, Diabetes Mellitus
EMA Tesavel
10 Jan 2008Diabetes Mellitus, Type 2, Diabetes Mellitus
EMA Ristaben
15 Mar 2010Diabetes Mellitus, Type 2, Diabetes Mellitus
EMA Sitagliptin SUN
9 Dec 2021Diabetes Mellitus, Type 2

All 9

EMA Sitagliptin Accord
25 Apr 2022Diabetes Mellitus, Type 2
FDA Zituvio
18 Oct 2023Diabetes Mellitus, Type 2
FDA Brynovin
16 Jan 2025Diabetes Mellitus, Type 2

Repurposing

Cardiovascular disease
Phase 3Results posted1 trial
Obesity
Phase 4Results posted2 trials
Heart failure
Phase 4Active, not recruiting2 trials
Osteoporosis
Phase 3Completed1 trial
Myocardial infarction
Phase 4Completed1 trial
Coronary artery disease
Phase 4Results posted2 trials

All 39

Atherosclerosis
Phase 3Results posted2 trials
Parkinson's disease
Phase 4Results posted1 trial
Insulin resistance
Phase 4Results posted7 trials
Type 1 diabetes
Phase 3Terminated8 trials
Postmenopausal osteoporosis
Phase 3Completed1 trial
Polycystic ovary syndrome
Phase 4Results posted4 trials
Hyperglycemia
Phase 4Results posted7 trials
Acute coronary syndrome
Phase 4Status unknown1 trial
Liver cirrhosis
Phase 4Completed1 trial
Lung disease
Phase 3Terminated1 trial
Hypoglycemia
Phase 4Completed3 trials
Glucose intolerance
Phase 4Completed3 trials
Prediabetic state
Phase 4Completed2 trials
Lewy body disease
Phase 4Results posted1 trial
Cystic fibrosis
Phase 3Terminated2 trials
Reperfusion injury
Phase 3Status unknown1 trial
Non-alcoholic fatty liver disease
Phase 2Results posted2 trials
Myelodysplastic syndrome
Phase 2Results posted1 trial
Psoriasis
Phase 2Results posted2 trials
Sensorineural hearing loss
Phase 2/3Status unknown1 trial
Thrombocytopenia
Phase 2Status unknown1 trial
Glioblastoma
Phase 2Recruiting2 trials
non-Hodgkin lymphoma
Phase 2Results posted2 trials
Blood coagulation disorder
Phase 2Status unknown1 trial
Brain neoplasms
Phase 2Recruiting1 trial
Optic atrophy
Phase 2/3Status unknown1 trial
Colorectal neoplasm
Phase 1/2Recruiting1 trial
Infertility
Phase 1/2Status unknown1 trial
Hepatitis C
Phase 1Terminated1 trial
Renal insufficiency
Phase 1Completed1 trial
Chronic hepatitis c
Phase 1Terminated1 trial
Gastroparesis
Phase 1Completed1 trial
Glioma
Phase 1Recruiting1 trial

In trials

Chronic kidney failure
Phase 4Terminated3 trials
Acromegaly
Phase 4Results posted1 trial
Chronic renal insufficiency
Phase 3Results posted2 trials
Hyperlipidemias
Phase 3Results posted2 trials
Peptic ulcer
Phase 2/3Status unknown1 trial
Graft vs host disease
Phase 2Results posted2 trials

All 12

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 2Results posted2 trials
Leukemia, Myeloid, Acute
Phase 2Results posted2 trials
Precursor cell lymphoblastic leukemia lymphoma
Phase 2Results posted2 trials
Advanced Renal Cell Carcinoma
Phase 1Recruiting1 trial
Follicular lymphoma
Phase 1Completed1 trial
Hepatic insufficiency
Phase 1Completed1 trial

Stopped

NCT00832624TerminatedType 2 diabetes
Business Reasons
NCT00936663TerminatedType 2 diabetes
lack of funding
NCT00939939TerminatedType 2 diabetes
Recruitment failure
NCT01970462TerminatedType 2 diabetes
Recruitment
NCT02015910TerminatedType 2 diabetes
Terminated by the sponsor due to slow enrollment
NCT00853944TerminatedType 1 diabetes
Sponsor withdrew funding du to lack of enrollment. Lack of enrollment was due to decrease in number of islet transplant procedures

All 8

NCT00967798TerminatedCystic fibrosis
Could not achieve target enrollment
NCT01567540TerminatedChronic hepatitis c
New treatments available, which prevents additional recruitment.